| Market Capitalization (Millions $) |
1,272 |
| Shares
Outstanding (Millions) |
144 |
| Employees |
121 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-207 |
| Cash Flow (TTM) (Millions $) |
158 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapies for Duchenne muscular dystrophy (DMD). DMD is a rare genetic disease that causes progressive muscle degeneration and weakness. The company aims to harness the power of gene therapy to address the underlying cause of DMD and potentially provide long-lasting benefits for patients.
Solid Biosciences is currently conducting clinical trials to test the safety and efficacy of its lead product candidate, SGT-001. SGT-001 is designed to deliver a functional copy of the dystrophin gene, which is responsible for producing a protein that is vital for muscle fiber stability. By replacing the faulty dystrophin gene with a healthy one, the company hopes to restore dystrophin production and improve the muscle function of DMD patients.
The company is also developing other potential gene therapies for DMD, including gene editing and gene regulation technologies. Solid Biosciences is committed to collaborating with the DMD community, including patients, caregivers, and advocacy groups, to ensure the development of therapies that meet their needs.
Solid Biosciences was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company has received significant funding from various sources, including venture capital firms and government grants, to support its research and development efforts.
Company Address: 500 Rutherford Avenue, Third Floor Charlestown 2129 MA
Company Phone Number: 337-4680 Stock Exchange / Ticker: NASDAQ SLDB
|
0.42% 